From “The Way Forward" Conference: Dr. Leonard S. Schleifer, Co-Founder, Regeneron Pharmaceuticals

Regeneron's Core Therapeutic Strategy

• Dr. Leonard Schleifer defines antibody therapy as an attempt to imitate the adaptive immune system's "random generator" process, which naturally takes weeks to months to produce neutralizing weapons against a virus.
• The company's approach prioritizes providing the body with "passive immunity" (similar to maternal antibodies transferred via placenta or breast milk) to neutralize the virus immediately before the patient's own immune system can respond.
• Regeneron utilized its proprietary "magical mice" platform—originally conceived by co-founder George Yancopoulos—to generate human antibodies, achieving a record-breaking development timeline of roughly five to six months from virus identification to patient administration for Ebola.

Rationale for Antibody Cocktail Design

• Regeneron selected a two-antibody "cocktail" strategy specifically to prevent the selection of viral escape mutants, a risk observed in single-antibody approaches for viruses like HIV.
• Laboratory experiments published in Science demonstrated that while single antibodies failed to neutralize the virus once variants emerged, the simultaneous binding of two distinct antibodies to different locations on the viral spike protein (comparable to gripping a football on opposite ends) effectively blocked resistance.
• Schleifer expressed concern that single-antibody therapies could inadvertently drive mutations in immunodominant domains, potentially undermining the efficacy of future vaccines.
• The cocktail's dual-binding mechanism was validated to prevent escape variants in replicating model systems, reinforcing the decision to delay clinical trials until a combination was secured rather than rushing a single-agent approach.

Clinical Development Timeline and Target Populations

• Clinical trials are targeting three distinct patient groups: those currently hospitalized, recently infected individuals, and high-risk populations in a prophylactic setting.
• Schleifer identifies the anticipated data release in late summer regarding newly infected patients as the "sweet spot" for demonstrating efficacy.
• The primary therapeutic goals are to decrease viral expression duration, reduce patient infectivity, and prevent severe disease progression if administered early in the infection timeline.
• The therapy is not intended as a mass vaccine but rather as a high-impact intervention for specific high-risk groups or immediate post-exposure scenarios.

Industry Acceleration and Technological Convergence

• Schleifer attributes the accelerated timeline from virus isolation to potential therapeutics (within 12 months) to the parallel advancement of biological wet sciences and enabling technologies.
• Unlike the HIV era, where therapeutics took decades to become manageable, Regeneron's current success relies on the intersection of deep molecular biology understanding with rapid technological platforms for scaling protein production and sequencing.
• The company's technology allows for immediate response to new viral variants; Schleifer noted that upon media reports of a new variant, internal teams confirmed their cocktail remains effective within hours.
• While optimistic about the eventual development of vaccines and therapeutics, Schleifer cautioned against overpromising, acknowledging that significant work remains before these tools are widely deployed.

Forward-Looking Statements and Context

• Regeneron plans to publish detailed preclinical data in Science to demonstrate the superiority of the cocktail approach over single-antibody strategies.
• The company maintains an intensive focus on ensuring the safety and efficacy of the cocktail to avoid downstream negative impacts on vaccine design.
• Schleifer expressed optimism that the biopharmaceutical industry is capable of delivering a scientific solution to the pandemic, describing the current moment as potentially transformational.
• The company's approach to scaling production and understanding virus biology has advanced significantly compared to 20 years ago, allowing for the rapid identification and neutralization of thousands of variants.